Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/14/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
45 |
| 05/15/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
40 |
| 11/14/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
51 |
| 08/13/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
47 |
| 05/15/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
43 |
| 11/13/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
53 |
| 08/14/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
74 |
| 05/15/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
42 |
| 11/10/16 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
50 |
| 08/11/16 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
49 |
